News

Understanding the Altimmune Class Action Lawsuit for Investors

Understanding the Altimmune Class Action Lawsuit for Investors

The Class Action Lawsuit Against Altimmune

Investors affected by the recent events surrounding Altimmune (NASDAQ: ALT) have an opportunity to participate in an important class action lawsuit. The lawsuit was launched by Bragar Eagel & Squire, P.C., a renowned law firm specializing in stockholder rights. It pertains to all individuals who acquired securities of Altimmune between August 10, 2023, and June 25, 2025, during what is referred to as the 'Class Period.' This is a crucial time frame for any stakeholders who have been impacted by the company's performance and decisions.

Key Dates and Actions for Investors

Investors are advised that there is an important deadline: October 6, 2025. By this date, individuals wishing to be included in this lawsuit must file to be appointed as lead plaintiff. This is essential for those looking to make a stand against the alleged misrepresentations made by the company regarding its clinical trials and their outcomes.

Allegations Against Altimmune

The core of the lawsuit involves allegations that Altimmune provided misleading information about its product, particularly relating to the IMPACT Phase 2b MASH trial results of Pemvidutide. The complaint states that despite initial expectations of favorable outcomes, the company failed to achieve statistical significance in its primary endpoint analysis. This was highlighted in a press release dated June 26, 2025, where the company acknowledged that the trial did not meet the anticipated benchmarks.

Impact on Stock Price

The response to this news was swift and severe. The stock price of Altimmune plummeted from $7.71 per share to $3.61, marking a staggering 53.2% drop in just one day. This dramatic decline has raised serious concerns among investors regarding the integrity of the company's communications and the potential for recovery in the stock value.

What Investors Should Do Now

If you are an investor who has acquired shares of Altimmune and have suffered losses, this lawsuit provides an avenue for you to seek justice. Communication is key during this time. It is advisable for investors to reach out to Bragar Eagel & Squire, P.C. for further guidance on their rights and options. They can be contacted directly by phone, allowing you to discuss your individual situation with a legal professional.

Legal Representation and Support

Bragar Eagel & Squire has extensive experience representing both individual and institutional investors in cases like this. They emphasize that there is no cost to you for seeking advice or representation, which means you can explore your options without financial obligation. They aim to keep clients informed and supported throughout the legal process.

About the Law Firm

Bragar Eagel & Squire, P.C. is recognized for its dedication to advocating for investors facing complex litigation related to securities and financial practices. With offices across the United States, including New York, California, and South Carolina, the firm is well-equipped to handle cases like the one against Altimmune. Their commitment is to protect shareholder rights, ensuring that investors have a voice in matters that significantly impact their financial interests.

Frequently Asked Questions

What is the deadline to join the Altimmune class action lawsuit?

The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 6, 2025.

Who can participate in this lawsuit?

Any individual or entity that purchased or otherwise acquired Altimmune securities during the specified Class Period can participate.

What are the allegations against Altimmune?

The lawsuit alleges that Altimmune misled investors about the results of its IMPACT Phase 2b MASH trial, specifically regarding the statistical significance of the trial results.

How did the trial results affect Altimmune's stock price?

Following the announcement of disappointing trial results, Altimmune's stock price fell dramatically from $7.71 to $3.61 in a single day, which was a decrease of more than 53%.

How can I contact Bragar Eagel & Squire for more information?

Investors can reach out to Bragar Eagel & Squire directly via phone at (212) 355-4648 or through their email contact options to discuss their legal rights and options.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 165

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 58

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 148

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 247

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 89

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading

Top 5 Most Recently Viewed Articles

Verizon Secures $66 Million EIS Partnership with Coast Guard

Updated Category News Views 283

Verizon Awarded $66 Million Enterprise Infrastructure Solutions Contract In a significant development, Verizon Business has been awarded a substantial contract valued at up to $66 million by the U.S. Coast Guard. This eight-year Enterprise Infrastructure Solutions (EIS) task order represents a robust commitment to enhancing the Coast Guard's communication and operational...

Continue Reading
Icelandic Glacial Becomes Laver Cup 2025's Official Water

Updated Category News Views 168

Icelandic Glacial to Hydrate Laver Cup 2025 Attendees Icelandic Glacial™, recognized for its exceptional quality and purity, has been designated as the Official Water for the highly anticipated Laver Cup 2025. This prestigious tournament is scheduled to take place at the Chase Center, showcasing top-tier men's tennis. A Perfect Fit for a Grand Event Coming from the...

Continue Reading
Dick's Sporting Goods Shows Promise for Q3 Amid Market Trends

Updated Category News Views 196

Dick's Sporting Goods Anticipates Strong Q3 Results Dick's Sporting Goods Inc. (NYSE: DKS) is gearing up for its fiscal third-quarter earnings report, creating buzz among investors eager to understand how the retailer is managing consumer demand and its recent strategic moves. As the company prepares to disclose its earnings, the market remains cautiously optimistic,...

Continue Reading
HyOrc Corporation Charts New Path with Green Fuel Innovations

Updated Category News Views 165

HyOrc Corporation's Strategic Market Transformation HyOrc Corporation (OTCID: HYOR) is making significant strides in the clean energy sector with a recent change in its trading symbol on the OTC markets. This evolution reflects not only a fresh identity but also the dynamic advancements the company is achieving in green fuel technologies and hydrogen mobility....

Continue Reading
Exploring Nature Through Art: BlackBook's New Exhibition

Updated Category News Views 227

BlackBook Presents Unveils a Unique Art Exhibition BlackBook Presents is set to embark on an exciting journey with its upcoming art exhibition titled Mother Nature in the Bardo. This innovative presentation, in collaboration with UNESCO's GEM Report, aims to foster meaningful discussions about art, culture, and their profound connection to environmental issues. Through an...

Continue Reading